胃肠道间质瘤的联合治疗

Combined Therapy of Gastrointestinal Stromal Tumors.

作者信息

Rutkowski Piotr, Hompes Daphne

机构信息

Department of Soft Tissue, Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Roentgena 5, Warsaw 02-781, Poland.

Department of Surgical Oncology, University Hospitals Gasthuisberg Leuven, Herestraat 49, Leuven 3000, Belgium.

出版信息

Surg Oncol Clin N Am. 2016 Oct;25(4):735-59. doi: 10.1016/j.soc.2016.05.006. Epub 2016 Aug 3.

DOI:10.1016/j.soc.2016.05.006

PMID:27591496

Abstract

Radical surgery is the mainstay of therapy for primary resectable, localized gastrointestinal stromal tumors (GIST). Nevertheless, approximately 40% to 50% of patients with potentially curative resections develop recurrent or metastatic disease. The introduction of imatinib mesylate has revolutionized the therapy of advanced (inoperable and/or metastatic) GIST and has become the standard of care in treatment of patients with advanced GIST. This article discusses the proper selection of candidates for adjuvant and neoadjuvant treatment in locally advanced GIST, exploring the available evidence behind the combination of preoperative imatinib and surgery.

摘要

根治性手术是原发性可切除局限性胃肠道间质瘤（GIST）治疗的主要手段。然而，约40%至50%接受潜在根治性切除的患者会出现复发或转移性疾病。甲磺酸伊马替尼的引入彻底改变了晚期（不可切除和/或转移性）GIST的治疗方式，并已成为晚期GIST患者治疗的标准疗法。本文讨论了局部晚期GIST辅助和新辅助治疗候选者的合理选择，探讨术前伊马替尼与手术联合应用背后的现有证据。